Exceeded Target Enrollment by 200% for a US-Based Phase 3 Gout Trial

Atlanta, GA –

We’re celebrating a significant milestone at Springer Wellness & Restorative Health, where Robert Springer, MD, one of our principal investigators, has successfully wrapped enrollment for a Phase 3 gout study — and delivered truly impressive results:

– Exceeded target enrollment expectations by over 200%
– Screened the first patient on the same day the site was activated
– Led diversity enrollment with 78% of enrolled participants representing diverse populations

Dr. Springer has led 35+ clinical trials with DelRicht Research, consistently setting the standard for excellence in clinical trial execution.

Thank you, Dr. Springer, for your leadership in moving medicine forward and ensuring broader representation in research.